C06再生醫療(細胞治療、基因治療、組織工程等)

Invion is an Australian life-sciences company focussed on transforming Photodynamic Therapy (PDT) for novel and effective treatments for cancer. Invion is leading the global research and development of the Photosoft™ technology and holds the license and distribution rights to the Photosoft™ technology in multiple countries across Asian Pacific and North America.

PDTs have been around for decades, and some have even been approved by the US FDA. It involves the use of a photosensitive drug and a light source to activate the drug, but severe side effects and other limitations have hampered their widespread use. Invion's Photosoft has the potential to overcome many of these shortcomings. Results from a Phase 2 prostate cancer trial showed a 40-44% positive response rate and the treatment only had mild side effects and was well tolerated by participants who underwent six rounds of the treatment. Further, Invion is currently undertaking a Phase I/II non-melanoma skin cancer trial (NMSC). In vivo studies show its lead drug candidate, INV043, is safe, non-scarring and non-toxic and only accumulates in cancer cells and not healthy tissue. Less invasive than surgery and with minimal side effects, Photosoft offers an alternative treatment option aimed at achieving complete tumour regression and long-lasting remission. Off the back of the NMSC trial, Invion plans to undertake a Phase Ib/II anogential clinical study in partnership with the Peter McCallum Cancer Centre.